Abstract
Chemotherapy-induced neutropenia (CIN) is a frequent complication in cancer patients receiving myelosuppressive chemotherapy, which can result in life-threatening infections requiring prolonged hospitalization and increasingly cost management. Furthermore, scheduled chemotherapy may be reduced or delayed as a result of CIN, which negatively affects prognosis. Granulocyte colony-stimulating factors (G-CSF) stimulate neutrophil production and maturation, and can therefore reduce the incidence and severity of neutropenia. A pegylated form of filgrastim, pegfilgrastim, has been developed, and various trials have shown that a single fixed dose (6 mg) per chemotherapy cycle is safe and effective in adult patients regardless of their body weight, thus making it a simple, effective, and well-tolerated option. This paper summarizes recent clinical data and analyses its place in the context of recent guidelines.
| Original language | English |
|---|---|
| Pages (from-to) | 1-18 |
| Number of pages | 18 |
| Journal | Trends in Medicine |
| Volume | 8 |
| Issue number | 1 |
| Publication status | Published - Jan 2008 |
Fingerprint
Keywords
- Chemotherapy
- Filgrastim
- Neutropenia
- Pegfilgrastim
- Prevention
ASJC Scopus subject areas
- Internal Medicine
- Pharmacology (medical)
Cite this
Clinical and economic benefit of G-CSF administration in the prevention of chemo-induced neutropenia. / Lorusso, Vito.
In: Trends in Medicine, Vol. 8, No. 1, 01.2008, p. 1-18.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical and economic benefit of G-CSF administration in the prevention of chemo-induced neutropenia
AU - Lorusso, Vito
PY - 2008/1
Y1 - 2008/1
N2 - Chemotherapy-induced neutropenia (CIN) is a frequent complication in cancer patients receiving myelosuppressive chemotherapy, which can result in life-threatening infections requiring prolonged hospitalization and increasingly cost management. Furthermore, scheduled chemotherapy may be reduced or delayed as a result of CIN, which negatively affects prognosis. Granulocyte colony-stimulating factors (G-CSF) stimulate neutrophil production and maturation, and can therefore reduce the incidence and severity of neutropenia. A pegylated form of filgrastim, pegfilgrastim, has been developed, and various trials have shown that a single fixed dose (6 mg) per chemotherapy cycle is safe and effective in adult patients regardless of their body weight, thus making it a simple, effective, and well-tolerated option. This paper summarizes recent clinical data and analyses its place in the context of recent guidelines.
AB - Chemotherapy-induced neutropenia (CIN) is a frequent complication in cancer patients receiving myelosuppressive chemotherapy, which can result in life-threatening infections requiring prolonged hospitalization and increasingly cost management. Furthermore, scheduled chemotherapy may be reduced or delayed as a result of CIN, which negatively affects prognosis. Granulocyte colony-stimulating factors (G-CSF) stimulate neutrophil production and maturation, and can therefore reduce the incidence and severity of neutropenia. A pegylated form of filgrastim, pegfilgrastim, has been developed, and various trials have shown that a single fixed dose (6 mg) per chemotherapy cycle is safe and effective in adult patients regardless of their body weight, thus making it a simple, effective, and well-tolerated option. This paper summarizes recent clinical data and analyses its place in the context of recent guidelines.
KW - Chemotherapy
KW - Filgrastim
KW - Neutropenia
KW - Pegfilgrastim
KW - Prevention
UR - http://www.scopus.com/inward/record.url?scp=39649110876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39649110876&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:39649110876
VL - 8
SP - 1
EP - 18
JO - Trends in Medicine
JF - Trends in Medicine
SN - 1594-2848
IS - 1
ER -